Drug discovery strategies targeting B7-H3 (CD276) in lung and gastric cancers: From biological validation to next-generation small molecules, biologics and cell-based immunotherapies.

Authors

Soorya Suresh, Surabhi Maurya, Kajal Singh, Kapil Sharma, Subhechchha Bar, Aastha Dagar, Vivek Uttam, Sandeep Singh, Farman Ahmad, Manju Jain, Raj Kumar, Gautam Sethi, Aklank Jain

Published in

Drug discovery today. Pages 104814. Sep 23, 2026. Epub Sep 23, 2026.

Abstract

B7 homolog 3 protein (B7-H3, also known as CD276) has emerged as a promising immune checkpoint target because of its high expression in solid tumors, limited presence in normal tissues and roles in immune evasion and tumor progression. This review focuses on the biological and therapeutic relevance of B7-H3 in lung and gastric cancers, where it contributes to oncogenic signaling, epithelial-mesenchymal transition, metabolic reprogramming and therapy resistance. We highlight its structural biology, target validation and molecular mechanisms while critically assessing therapeutic strategies, including monoclonal antibodies, antibody-drug conjugates, bispecific antibodies, CAR-based therapies and emerging small-molecule inhibitors. We also discuss biomarkers, medicinal chemistry and future directions for precision cancer therapy.

PMID:
42777908
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.